Question

A 62-year-old with symptomatic HFrEF (LVEF 30%) is on sacubitril/valsartan, carvedilol, and spironolactone. eGFR 58 mL/min/1.73 m², potassium 4.5 mEq/L, no diabetes. Which additional disease-modifying therapy should be initiated to reduce mortality and HF hospitalizations?

Accepted Answer

Start an SGLT2 inhibitor (e.g., dapagliflozin 10 mg daily)

Answer

Add ivabradine

Answer

Add hydralazine-isosorbide dinitrate

Answer

Start digoxin

Answer

Add vericiguat

Practice question

A 62-year-old with symptomatic HFrEF (LVEF 30%) is on sacubitril/valsartan, carvedilol, and spironolactone. eGFR 58 mL/min/1.73 m², potassium 4.5 mEq/L, no diabetes. Which additional disease-modifying therapy should be initiated to reduce mortality and HF hospitalizations?